Immune checkpoint inhibitors including anti-programmed cell death receptor (PD-1) (nivolumab and pembrolizumab) or anti-PD-ligand (PD-L1) (duralumab, atezolizumab, and avelumab) monoclonal antibodies are revolutionizing cancer therapy. The gene discussed is CD274; the disease is cancer.